{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:31:32Z","timestamp":1792643492043,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ophtha.2022.04.028","type":"journal-article","created":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T18:20:13Z","timestamp":1651947613000},"page":"974-985","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid"],"prefix":"10.1016","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8928-5599","authenticated-orcid":false,"given":"Arshad M.","family":"Khanani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2570-5766","authenticated-orcid":false,"given":"David M.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn J.","family":"Jaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7756-5091","authenticated-orcid":false,"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eser","family":"Adiguzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyi","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4625-3145","authenticated-orcid":false,"given":"Jeffrey S.","family":"Heier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.ophtha.2022.04.028_bib1","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1001\/jama.291.15.1900","article-title":"Age-related macular degeneration is the leading cause of blindness","volume":"291","author":"Bressler","year":"2004","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ophtha.2022.04.028_bib2","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1111\/bph.15459","article-title":"Emerging therapies and their delivery for treating age-related macular degeneration","volume":"179","author":"Thomas","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"14","key":"10.1016\/j.ophtha.2022.04.028_bib3","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.ophtha.2022.04.028_bib4","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.ophtha.2022.04.028_bib5","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ophtha.2022.04.028_bib6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2022.04.028_bib7","series-title":"EYLEA\u00ae (prescribing information)","year":"2011"},{"key":"10.1016\/j.ophtha.2022.04.028_bib8","series-title":"LUCENTIS\u00ae (prescribing information)","year":"2006"},{"issue":"2-a Suppl","key":"10.1016\/j.ophtha.2022.04.028_bib9","first-page":"S3","article-title":"Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration","volume":"24","author":"Wykoff","year":"2018","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.ophtha.2022.04.028_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12886-016-0207-3","article-title":"The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration\u2014a phase IV randomised clinical trial with ranibizumab: the FLUID study","volume":"16","author":"Arnold","year":"2016","journal-title":"BMC Ophthalmol"},{"issue":"4","key":"10.1016\/j.ophtha.2022.04.028_bib11","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s40123-020-00288-0","article-title":"Demographic and clinical factors that influence the visual response to anti-vascular endothelial growth factor therapy in patients with neovascular age-related macular degeneration: a systematic review","volume":"9","author":"Gill","year":"2020","journal-title":"Ophthalmol Ther"},{"issue":"2","key":"10.1016\/j.ophtha.2022.04.028_bib12","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ophtha.2012.08.008","article-title":"Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point","volume":"120","author":"Brown","year":"2013","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ophtha.2022.04.028_bib13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3928\/23258160-20130313-04","article-title":"SAVE (super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results","volume":"44","author":"Wykoff","year":"2013","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"9","key":"10.1016\/j.ophtha.2022.04.028_bib14","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.ophtha.2016.05.016","article-title":"Differential response to anti-VEGF regimens in age-related macular degeneration patients with early persistent retinal fluid","volume":"123","author":"Jaffe","year":"2016","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ophtha.2022.04.028_bib15","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.ophtha.2019.12.031","article-title":"Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration","volume":"127","author":"Nguyen","year":"2020","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ophtha.2022.04.028_bib16","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ophtha.2015.12.030","article-title":"Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study","volume":"123","author":"Holz","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2022.04.028_bib17","first-page":"1501","article-title":"Affinity and potency of RTH258 (ESBA1008), a novel inhibitor of vascular endothelial growth factor A for the treatment of retinal disorders","volume":"56","author":"Tietz","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2022.04.028_bib18","unstructured":"Novartis Europharm Limited, Beovu\u00ae, 2020, summary of product characteristics, Novartis Europharm Limited; Dublin, Ireland."},{"key":"10.1016\/j.ophtha.2022.04.028_bib19","series-title":"Beovu\u00ae (prescribing information)","year":"2019"},{"issue":"1","key":"10.1016\/j.ophtha.2022.04.028_bib20","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ophtha.2022.04.028_bib21","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","article-title":"Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial","volume":"124","author":"Dugel","year":"2017","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ophtha.2022.04.028_bib22","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1136\/bjophthalmol-2018-313682","article-title":"Visual benefit versus visual gain: what is the effect of baseline covariants in the treatment arm relative to the control arm? A pooled analysis of ANCHOR and MARINA","volume":"104","author":"Tufail","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.04.028_bib23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/OPTH.S125676","article-title":"Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis","volume":"11","author":"Spooner","year":"2017","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"10.1016\/j.ophtha.2022.04.028_bib24","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1097\/IAE.0000000000003194","article-title":"Retinal fluid and thickness as measures of disease activity in neovascular age-related macular degeneration","volume":"41","author":"Kaiser","year":"2021","journal-title":"Retina"},{"issue":"12","key":"10.1016\/j.ophtha.2022.04.028_bib26","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1016\/j.ophtha.2015.08.009","article-title":"Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results","volume":"122","author":"Wykoff","year":"2015","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ophtha.2022.04.028_bib27","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.oret.2016.12.004","article-title":"Randomized trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: 2-year results of the TREX-AMD study","volume":"1","author":"Wykoff","year":"2017","journal-title":"Ophthalmol Retina"},{"issue":"7","key":"10.1016\/j.ophtha.2022.04.028_bib28","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of inflammation, retinal vasculitis and retinal occlusion-related events with brolucizumab: post-hoc review of HAWK and HARRIER","volume":"128","author":"Mon\u00e9s","year":"2021","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ophtha.2022.04.028_bib29","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/jamaophthalmol.2021.4585","article-title":"Safety outcomes of brolucizumab in neovascular age-related macular degeneration: results from the IRIS Registry and Komodo Healthcare Map","volume":"140","author":"Khanani","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.04.028_bib30","author":"Novartis"},{"issue":"8","key":"10.1016\/j.ophtha.2022.04.028_bib31","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1007\/s00417-021-05073-8","article-title":"PERSEUS 24-month analysis: a prospective non-interventional study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in Germany in patients with neovascular age-related macular degeneration","volume":"259","author":"Eter","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"8","key":"10.1016\/j.ophtha.2022.04.028_bib32","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jamaophthalmol.2020.2309","article-title":"Evaluation of month-24 efficacy and safety of epimacular brachytherapy for previously treated neovascular age-related macular degeneration: the MERLOT randomized clinical trial","volume":"138","author":"Jackson","year":"2020","journal-title":"JAMA Ophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642022003347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642022003347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:11:59Z","timestamp":1758982319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642022003347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0161642022003347"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2022.04.028","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2022.04.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}